As the classical immune-suppressive CTLA4-CD80/CD86 and PD-1 (PDCD1)-PD-L1/L2 (CD274/PDCD1LG2) pathways were found to be minimally involved, they may have uncertain functions in treatment-naïve HCC patients. The gene discussed is CD86; the disease is hepatocellular carcinoma.